DBVT | Ticker Profile - Titan Protect

DBVT

DBV Technologies S.A.

Healthcare · Biotechnology · NCM

$16.59

Data: 2026-05-28

✓ ETHICAL PASS

Unknown MOAT

HIGH

Data Confidence: 85.7%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$1.1B

Total market value of the company

Trailing P/E

N/A

Forward P/E

-37.92

Based on estimated future earnings — lower means cheaper

Rev Growth

+12.5%

Year-over-year revenue change

Profit Margin

0.0%

How much profit the company keeps from each dollar of revenue

ROE

-158.9%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$46.40

+180% from current price — median analyst estimate

Recommendation

NONE

Consensus view from 6 analysts covering this stock

About DBV Technologies S.A.

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs include celiac disease. In addition, the company develops Viaskin technology platform, a platform to potentially treat food allergy. It has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Châtillon, France.

https://www.dbv-technologies.com

Country: France Employees: 161 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKDOWN

Price trending down — defensive positioning

Sharpe Ratio

0.921

Good returns relative to risk taken

Kelly Fraction

0.1912

Suggested allocation is meaningful — the edge justifies a position

Calmar Ratio

5.130

Returns exceed worst-case losses — strong risk profile

Annual Return

309.1%

Historical annualised return based on price data

Max Drawdown

-60.3%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

-0.24

Very low correlation to market moves

52W High

$26.19

37% below the year high

52W Low

$7.53

120% above the year low

Avg Volume

246,929

Average daily shares traded — higher means easier to buy and sell

Short Ratio

9.1

Days it would take all short sellers to cover — higher means more crowded

Short % Float

3.1%

Low short interest — limited bearish positioning

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-4.50

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

2.93

Heavy leverage — higher financial risk if revenues decline

Current Ratio

4.76

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

4.72

Like current ratio but excludes inventory — stricter test

Gross Margin

100.0%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-5,311.1%

Profit from core operations before interest and tax

Free Cash Flow

$-87,206,000

Negative — the business is spending more than it generates

Revenue (TTM)

$6M

Total revenue over the last 12 months

Net Income

$-167,447,008

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$54.48

Target Median

$46.40

Target Low

$5.93

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go